Glaxosmithkline Pharmaceuticals Limited (glaxo) Q2 FY27: Growth Surges with Key Portfolio Transformation

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) reports Q2 FY27 growth, driven by portfolio transformation and innovation.